Skip to main content
. Author manuscript; available in PMC: 2016 Mar 23.
Published in final edited form as: Epilepsy Res. 2015 Feb 14;112:18–26. doi: 10.1016/j.eplepsyres.2015.02.003

Table 1.

Baseline Demographic and Clinical Characteristics of Cohort.

Total (n = 133) LGS (n = 39) Not LGS (n = 94) p
Sex (M/F) 72/61 17/22 55/39 0.25
Hispanic ethnicity (n, percent) 7 (5) 1 (2) 6 (6) 0.67
Race (n, percent)
  White 96 (75) 26 (68) 70 (78) 0.27
  Black 15 (12) 6 (16) 9 (10)
  Asian 10 (8) 5 (13) 5 (5)
  Other or Unknown 7 (5) 1 (3) 6 (7)
Age at seizure onset (years; median, range) 1 (<1–13) 0.5 (<1–7) 1.5 (<1–13) 0.02
Age at RFM initiation (years; median, range) 10 (0.9–25.7) 11.3 (2.1–23.5) 10 (0.9–25.7) 0.53
Duration of follow up (months; median, range) 20 (1–30) 23 (9–30) 19 (1–27) 0.01
Start time of RFM 0.12
  January–June 2009 64 (48) 25 (64) 39 (41)
  July–December 2009 30 (23) 7 (18) 23 (24)
  January–June 2010 30 (23) 6 (15) 24 (26)
  July–December 2010 9 (7) 1 (3) 8 (9)
Mode of onset
  Focal (n, percent) 31 (23) 31 (32)
  Generalized (n, percent) 49 (37) 19 (49) 30 (32)
  Both Focal and Generalized (n, percent) 50 (38) 20 (51) 30 (32)
  Undetermined (n, percent) 3 (2) 3 (3)
Number of seizure types (median, range) 2 (1–6) 3 (1–6) 2 (1–4) 0.002
AEDs prior to RFM (median, range) 6 (2–13) 4 (2–13) 7 (2–13) 0.11
Patients with atonic seizures (n, percent) 47 (35) 26 (67) 21 (22) <0.001
Patients with tonic seizures (n, percent) 40 (30) 20 (51) 20 (21) <0.001
Fast titration (n, percent) 39 (29) 11 (28) 28 (30) 0.56
Maximum RFM dose (mg/kg/day; median, range) 45 (4–105) 49 (4–84) 44 (6–105) 0.22
Concurrent AEDs at RFM start (median, range) 2 (0–4) 2 (0–4) 2 (0–4) 0.65
Patients on concurrent valproate (n, percent) 36 (27) 8 (21) 28 (30) 0.15
Patients on the ketogenic diet (n, percent) 17 (13) 1 (3) 16 (17) 0.18
Patients with vagus nerve stimulator (n, percent) 41 (31) 15 (38) 26 (27) 0.32